Novo Nordisk Seeks $830 Million in Damages: Court Freezes KBP Biosciences’ Assets Amid Licensing Dispute
In the competitive world of pharmaceuticals, licensing agreements play a critical role in fostering innovation and ensuring ethical practices. A recent legal dispute involving Novo Nordisk—a global leader in diabetes care—and KBP Biosciences has highlighted the potential consequences of alleged deception in such agreements. With Novo Nordisk seeking a substantial $830 million in damages, the […]